Key factors in developing the trinitrobenzene sulfonic acid-induced post-inflammatory irritable bowel syndrome model in rats

Hong-Yan Qin, Hai-Tao Xiao, Justin CY Wu, Brian M Berman, Joseph JY Sung, Zhao-Xiang Bian

Hong-Yan Qin, Hai-Tao Xiao, Zhao-Xiang Bian, School of Chinese Medicine, Hong Kong Baptist University, Hong Kong 999077, China
Justin CY Wu, Joseph JY Sung, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong 999077, China
Brian M Berman, Center for Integrative Medicine, University of Maryland, School of Medicine, Baltimore, MD 21201, United States

Author contributions: Qin HY performed the majority of experiments and data analysis, and wrote the manuscript; Xiao HT participated in the animal experiments; Wu JCY participated in data analysis; Berman BM participated in experimental design and reviewing of the manuscript; Sung JJY participated in the critical review of the manuscript; Bian ZX participated in the conception, experimental design and critical review and writing of the manuscript.

Supported by Hong Kong Jockey Club Institute of Chinese Medicine, No. JCICM-4-07
Correspondence to: Zhao-Xiang Bian, Professor, School of Chinese Medicine, Hong Kong Baptist University, Hong Kong 999077, China. bzxiang@hkbu.edu.hk
Telephone: +852-34112905 Fax: +852-34112929
Received: October 22, 2011 Revised: December 15, 2011
Accepted: December 22, 2011
Published online: May 28, 2012

Abstract

AIM: To investigate the key factors in developing the trinitrobenzene sulfonic acid (TNBS)-induced post-inflammatory irritable bowel syndrome (PI-IBS) model in rats.

METHODS: TNBS was administered to rats at the following conditions: (1) with different doses (20, 10, 5 mg/0.8 mL per rat); (2) with same dose in different concentrations (20 mg/rat, 25, 50 mg/mL); (3) in different ethanol percentage (25%, 50%); and (4) at depth either 4 cm or 8 cm from anus. At 5 d and 4 wk after TNBS administration, inflammation severity and inflammation resolution were evaluated. At 4 and 8 wk after TNBS application, visceral hyperalgesia and enterochromaffin (EC) cell hyperplasia were assayed by abdominal withdrawal reflex test, silver staining and capillary electrophoresis.

RESULTS: Our results showed that: (1) TNBS induced dose-dependent acute inflammation and inflammation resolution. At 5 d post TNBS, the pathological score and myeloperoxidase (MPO) activity in all TNBS treated rats were significantly elevated compared to that of the control (9.48 ± 1.86, 8.18 ± 0.67, 5.78 ± 0.77 vs 0, and 3.55 ± 1.11, 1.80 ± 0.82, 0.97 ± 0.08 unit/mg vs 0.14 ± 0.01 unit/mg, P < 0.05). At 4 wk post TNBS, the pathological score in high and median dose TNBS-treated rats were still significantly higher than that of the control (1.52 ± 0.38 and 0.80 ± 0.35 vs 0, P < 0.05); (2) Intracolonic TNBS administration position affected the persistence of visceral hyperalgesia. At 4 wk post TNBS, abdominal withdrawal reflex (AWR) threshold pressure in all TNBS-treated groups were decreased compared to that of the control (21.52 ± 1.73 and 27.10 ± 1.94 mmHg vs 34.44 ± 1.89 mmHg, P < 0.05). At 8 wk post TNBS, AWR threshold pressure in 8 cm administration group was still significantly decreased (23.33 ± 0.61 mmHg vs 36.79 ± 2.29 mmHg, P < 0.05); (3) Ethanol percentage affected the TNBS-induced inflammation severity and visceral hyperalgesia. In TNBS-25% ethanol-treated group, the pathological score and MPO activity were significantly lowered compared to that of the TNBS-50% ethanol-treated group, while AWR threshold pressure were significantly elevated (36.33 ± 1.33 mmHg vs 23.33 ± 1.33 mmHg, P < 0.05); and (4) TNBS (5 mg/0.8 mL per rat, in 50% ethanol, 8 cm from anus)-treated rats recovered completely from the inflammation with acquired visceral hyperalgesia and EC cell hyperplasia at 4 wk after TNBS administration.

CONCLUSION: TNBS dosage, concentration, intraco-
Ionic administration position, and ethanol percentage play important roles in developing visceral hyperalgesia and EC cell hyperplasia of TNBS-induced PI-IBS rats.

© 2012 Baishideng. All rights reserved.

Key words: Post-inflammatory; Irritable bowel syndrome; Rat model; Trinitrobenzene sulfonic acid; Key factors

Peer reviewer: Kwang Jae Lee, Professor, Department of Gastroenterology, Ajou University Hospital, San5, Woncheondong, Yeongtongku, Suwon 443-721, South Korea

Qin HY, Xiao HT, Wu JCY, Berman BM, Sung JYY, Bian ZX. Key factors in developing the trinitrobenzene sulfonic acid-induced post-inflammatory irritative bowel syndrome model in rats. World J Gastroenterol 2012; 18(20): 2481-2492 Available from: URL: http://www.wjgnet.com/1007-9327/full/v18/i20/2481.htm DOI: http://dx.doi.org/10.3748/wjg.v18.i20.2481

INTRODUCTION

Post-infectious irritable bowel syndrome (PI-IBS) is a subgroup of IBS in which the IBS patients developed their symptoms after recovery from an acute gastrointestinal infection[1-3]. The features of PI-IBS, such as urgency, loose stool, and abdominal pain, are very similar to those of the diarrhea-predominant IBS[4,5]. Prospective studies indicate that 3%-36% of enteric infections may lead to the generation of new IBS symptoms; the precise incidence mainly depends on the infecting organism and the host responses[1]. Though the term “PI-IBS” was first coined by Chaudhary and Truelove in 1962[6], little attention has been paid to it until recently[7]. The causes and/or underlying mechanisms of PI-IBS are still not fully understood, although it is believed that altered gut flora, changed intestinal permeability, activated gut immunity, and functional or structural changes in enteric nervous system are important factors[7,8].

Validated animal models, which aim to mimic one or more features of human disease, play important roles in the studies of mechanisms and potential therapeutic agents for diseases. Based on the current understanding of the clinical features and underlying mechanisms of PI-IBS, the ideal model for PI-IBS should bear the character with one or more features of IBS, such as visceral hypersensitivity, motility dysfunction, alterations in permeability or secretion, and enterochromaffin (EC) cell hyperplasia, and complete recovery from initial infection/inflammation[9]. The chemical agent-induced post-inflammatory IBS animal models have been widely used in mechanistic studies of PI-IBS because the chemical agent-induced inflammatory response and host immune activation can, to some extent, mimic the characteristics of PI-IBS[10,11], and these alterations are consistent with the findings from clinical studies[10,11]. Our previous systematic review showed that the trinitrobenzene sulfonic acid (TNBS)-induced model is the most commonly used PI-IBS model[12], and the major features of IBS (i.e., visceral hypersensitivity, motility dysfunction, and alteration in permeability or secretion), can be developed in this model. However, there are large variations in the protocol of model development, such as TNBS dosage and concentration, position of intracolonic TNBS administration, ethanol percentage, and the optimal time after intracolonic TNBS administration for model application, etc[7]. These variations make comparison between studies to be very difficult, if not impossible.

As a chemical hapten, TNBS is capable of binding to tissue proteins and stimulating T helper 1 cell mediated immunity; thus, it has been widely used to induce acute colitis by intracolonic administration[13]. It has been reported that TNBS-induced acute inflammation and damage becomes maximal from 3 d to 1 wk after instillation[9]. Previous studies have shown that TNBS had dose-dependent effects on mucosal inflammation[14,15], suggesting dosage is an important factor in TNBS-induced inflammation severity and colonic recovery from such inflammation. However, in previous studies on the TNBS-induced PI-IBS model, the dosage of TNBS varied from 20 mg per rat to 30 mg per rat[7]. Further, there is no consensus on how long it will take for TNBS-induced inflammation recovery after TNBS administration. Some studies, using TNBS (30 mg/rat), took 4 or 6 wk for inflammation recovery after intracolonic TNBS administration[16,17], while another study took at least 8 wk[18]. In addition, TNBS is generally administered into the colon lumen at either 4 cm or 8 cm from the anus[7]. Given the anatomical and physiological differences between these two sites (descending colon vs transverse colon), it is possible - but not known - whether the position of TNBS administration influences the results. Furthermore, ethanol is routinely used as a breaker to the mucosal barrier in TNBS-induced PI-IBS studies, and previous studies have shown that 30%-50% ethanol alone induced acute inflammation and hyperemia[18,19]. The commonly used ethanol percentage in developing TNBS-induced PI-IBS model are 25% and 50%[14,20], and whether the ethanol percentage influences the development of TNBS-induced PI-IBS rat model is still not clear.

Concerning the above variations in developing protocol of the TNBS-induced PI-IBS rat model, the present study aimed to investigate the effects of some impact factors (i.e., TNBS dosage and concentration, position of TNBS administration, and ethanol percentage) on TNBS-induced acute inflammation, inflammation resolution, and later acquired features of IBS (i.e., visceral hyperalgesia and EC cell hyperplasia).

MATERIALS AND METHODS

Materials

TNBS (2,4,6-trinitrobenzenesulfonic acid solution), hexadecyltrimethylammonium bromide, o-dianisidine dihydrochloride, sodium hyposulfite, and silver nitrate were

WJG | www.wjgnet.com 2482 May 28, 2012 | Volume 18 | Issue 20 |
all purchased from Sigma-Aldrich (St. Louis, MO, United States). Chloral hydrate was purchased from Kou Hing Hong Scientific Supplies (Hong Kong, China).

**Animals**

Male Sprague-Dawley rats (aged 6 wk with body weight around 220 g) were obtained from the Laboratory Animal Services Centre, The Chinese University of Hong Kong. Rats were housed 5 per cage and maintained at 25 °C under 12 h-12 h alternating light-dark cycle with free access to food and water. Rats were maintained in laboratory conditions for 1 wk to adapt to the environment before each experiment. All animal studies were carried out in accordance with the guidelines of the Committee on Use of Human and Animal Subjects in Teaching and Research, Hong Kong Baptist University.

**Experimental design**

The rats were randomly divided into 7 groups. TNBS (20 mg/0.4 mL per rat) was given to rats in group 1 (n = 10). The rats in group 2 (n = 10), group 3 (n = 10), and group 4 (n = 14) were intracolonic administered with TNBS at a dose of 20, 10 and 5 mg per rat in 0.8 mL ethanol, respectively. In the above 4 groups, TNBS in 50% ethanol saline solution was administered at a depth of 8 cm from the anus. Rats in group 5 (n = 14) were given TNBS (5 mg/0.8 mL per rat in 50% ethanol) at a depth of 4 cm from the anus, while rats in group 6 (n = 14) were given TNBS (5 mg/0.8 mL per rat in 25% ethanol) at 8 cm from the anus. Group 7 (n = 14) was set as a control; rats in this group were given saline 0.8 mL at a depth of 8 cm from the anus (Table 1).

Five days after TNBS or saline administration, 4 rats in each group were selected randomly, and the colon tissues from these rats were harvested for inflammation evaluation. The remaining rats were allowed to recover until the pain threshold pressure was measured. At 4 wk after TNBS administration, five rats in each group were selected randomly for pain threshold pressure evaluation; then the colon tissues were collected for inflammation recovery examination. At 8 wk after TNBS administration, the rest of the rats in each group went through pain threshold pressure evaluation to test the stability of visceral hyperalgesia. In order to further investigate if the TNBS-induced PI-IBS model had EC cell hyperplasia in the colon tissue, a part of proximal and distal colon tissues were also collected for EC cell number counting and serotonin [5-hydroxytryptamine (5-HT)] content determination.

**Induction of colitis**

Colitis was induced according to previous reports, with little modification[10]. Briefly, rats were fasted for 24 h before experiments, and then deeply anesthetized with chloral hydrate (350 mg/kg, i.p.). A fine plastic catheter (external diameter = 0.96 mm) was gently inserted into the descending colon at a depth of 4 cm or 8 cm from anus. The rats were kept in a head-down vertical position, and then TNBS was instilled slowly into the colon lumen within 1 min. After TNBS instillation, the catheter was left in place for 1 min and then slowly removed. The TNBS-treated rats were left on a warm mound of bedding in head-down position to prevent drug leakage until they regained consciousness. The control rats were similarly administered with 0.8 mL saline instead of TNBS.

**Tissue preparation**

Rats were deeply anesthetized with chloral hydrate (350 mg/kg, i.p.); then an approximately 6 cm long piece of colon tissue with drug administration position in the middle was removed. After the photos were taken, 3 cm of the distal part (proximal to the anus) was fixed in 4% paraformaldehyde for histological evaluation, the remaining 3 cm (distal to the anus) was placed in liquid nitrogen and stored in a freezer at -80 °C for myeloperoxidase activity assay. In addition, approximate 3 cm of proximal colon (1-2 cm from cecum) and 3 cm of distal colon (1-2 cm from anus) tissue were also harvested from the PI-IBS model rats; the proximal part (about 1 cm) was fixed in 4% paraformaldehyde for EC cell number counting; the rest was placed in liquid nitrogen, and stored at -80 °C for 5-HT content determination.

**Histological evaluation**

The colon sections (5 μm thick) collected at 5 d and 4 wk after TNBS administration were all stained with hematoxylin and eosin (H and E). Masson trichrome staining was performed on sections collected at 4 wk after TNBS administration for fibrosis evaluation. All sections were examined under a Nikon light microscope (Nikon Inc., Japan). The severity of the acute inflammation and the degree of inflammation resolution was graded using the macroscopic and histological scoring criteria (Tables 2 and 3), which were modified based on previous reports[22,23] according to the pathologist's suggestion. Five random fields were selected in each slide; images were captured with 100 × magnifications and analyzed using Image J NIH software. For fibroplasia evaluation, the area stained blue by Masson trichrome staining was measured and adjusted to reflect the total area of the colon tissue[23].

**Myeloperoxidase activity assay**

Myeloperoxidase (MPO) is an enzyme released by neu-
trophils in tissue under inflammatory conditions, and the
level of MPO activity correlates directly with severity of
inflammation\textsuperscript{[17]}. In this study, MPO activity was
measured by the modified method described by Krawisz \textit{et al}\textsuperscript{[18]} and Diop \textit{et al}\textsuperscript{[18]}. Briefly, the colon tissues were cut
into small pieces and homogenized in 0.5% hexadecyltri-
methylammonium bromide 1 mL per 100 mg of colon
tissue. The homogenates were centrifuged at 19 000 \textit{g}
at 4 \textdegree C for 15 min. Aliquots of 80 mL supernatant were
mixed with 120 \mu L potassium phosphate buffer (50
mmol, pH 6.0) with 0.005\% o-dianisidine dihydrochlo-
ride and 0.1\% hydrogen peroxide. MPO activity was
-calculated from the rate of absorbance change during
1 min at 460 nm; one unit of MPO activity is equal to
1.13 \times 10\textsuperscript{2} changes in absorbance at 25 \textdegree C. The results were
-normalized to the wet weight of colon tissue and
expressed as MPO units/mg tissue.

Abdominal withdrawal reflex
Abdominal withdrawal reflex (AWR) test was performed
as previously described to detect the pain threshold pressure\textsuperscript{[19]}. Briefly, rats were lightly anesthetized with ether
in order to place a 6 cm long flexible latex balloon into the
descending colon and rectum through the anus. The
end of the balloon was secured at least 1 cm proximal to
the anal verge. Rats were then allowed to recover for at
least 30 min. The tube of the balloon was connected \textit{via}
a Y-connector to a sphygmomanometer and colorectal
distension was applied in increments of 5 mmHg until a visible contraction of the abdominal wall was ob-
served by an investigator blinded to the treatment. The
pain threshold pressure was defined as the intensity of
colorectal distension that elicited an observable AWR,
i.e., a sudden and persistent abdominal muscle contrac-
tion with abdomen lift off the platform (Score 3). The
pain threshold pressure of all groups was recorded and
-repeated five times with intervals of at least 5 min for
recovery.

Enterochromaffin cell counting
Tissue sections (5 \mu m thick) were deparaffinized in xy-
lene, and rehydrated with graded ethanol for silver staining
according to a method previously described, with
little modification\textsuperscript{[20]}. Sections were incubated with 5\%
ammoniacal silver solution for 4 h at room tempera-
ture, then 2 h in 56 \textdegree C and subsequently 12 h at room
temperature in a dark humidified chamber. After rinsing
with water, 5\% sodium hyposulfite was added and sec-
tions were incubated for 5 min at room temperature.
The brown to black silver precipitate in the cytoplasm
of EC cells was considered as a positive reaction. Five
random fields at 200\times magnifications for each section
were captured and saved in the same size and resolution
by a researcher blinded to treatment. After calibration,
the mucosal fields were circled, and the areas of mucosa
were calculated using Image J NIH software. EC cell
density was calculated and expressed as the number of
EC cells per mm\textsuperscript{2} of mucosal area.

Serotonin content assessment
5-HT content in the colonic tissue was assayed following
the previously reported procedure\textsuperscript{[21]}. Briefly, the colon
segment was homogenized in 15\% iced trichloroactic
acid; the supernatant of each sample was filtered using
0.22 \mu m filters and extracted with diethyl ether, then
the prepared samples were added to derivatization solu-
tion and analyzed by capillary electrophoresis with laser-
induced fluorescence detection.

Statistical analysis
Data are presented as mean \pm SE. Differences between
two groups were analyzed by Student \textit{t} test. When multiple
groups were compared, data were analyzed using
one-way analysis of variance followed by the Student-
Newman-Keuls test. Differences were considered sig-
ificant when \textit{P} < 0.05.

RESULTS
Effect of trinitrobenzene sulfonic acid concentration on
body weight and mortality rate
Based on the findings from our previous systematic re-
view, TNBS (20 mg/rat, in 50\% ethanol) was selected and
given to rats at 8 cm from anus in 0.4 or 0.8 mL volume.
As shown in Table 4, compared to the control group, the
body weight of TNBS-treated rats all decreased mark-
edly with loose and bloody stools at 5 d post-TNBS (\textit{P}
< 0.01). Moreover, the body weight in high-concentration
TNBS (50 mg/mL)-treated rats was significantly lowered
when compared to that treated with low-concentration
TNBS (25 mg/mL) (\textit{P} < 0.05), and 3 rats in the high-
concentration TNBS (50 mg/mL)-treated group were
found dead. At 4 wk after TNBS administration, the aver-
age body weight of high-concentration TNBS-treated
rats was still significantly decreased compared to that of
rats treated with low-concentration TNBS and saline
(\textit{P} < 0.05); no significant difference was found in the body
weight between low-concentration TNBS-treated rats and
the saline-treated ones.

Effect of trinitrobenzene sulfonic acid dosage on the
severity of acute inflammation and inflammation resolution
Five days after TNBS administration, the results from
MPO activity assay and histopathological evaluation
showed that, TNBS, when administered at the doses of

| Score | Appearance |
|-------|------------|
| 0     | Normal appearance |
| 1     | Ulceration with inflammation at 1 or 2 sites |
| 2     | More sites of ulceration and inflammation |
| 3     | Major sites of damage extending > 1.5 cm along length of colon |
| 4     | Major sites of damage extending > 3 cm along length of colon |
Table 3  Criteria of histological scoring in colon tissue

| Variables                  | Severity and scoring                                      |
|----------------------------|-----------------------------------------------------------|
| Ulceration                 | No ulcer Ulcerations not exceeding lamina muscularis mucosae Ulcerations exceeding submucosa |
| Edema                      | Normal thickness Submucosal expansion < 30% Few scattered cells |
| Inflammatory cells         | No infiltration Distributed but not dense Increase < 30% |
| Fibrosis                   | Normal collagen Increase 30%-50% Increase > 50% |

Table 4  Effects of trinitrobenzene sulfonic acid concentration on body weight and mortality rate

| Treatment | TNBS concentration | Body weight (g) | Mortality rate (%) |
|-----------|--------------------|-----------------|--------------------|
| Saline    |                    | 249.6 ± 26.7    | 0                  |
| TNBS 20 mg/0.8 mL per rat | 25 mg/mL       | 214.5 ± 16.8    | 33                 |
| TNBS 20 mg/0.4 mL per rat | 50 mg/mL       | 179.2 ± 21.4    | 33                 |

*P < 0.05, **P < 0.01 vs saline-treated group; ***P < 0.01 vs TNBS (20 mg/0.8 mL)-treated group. TNBS: Trinitrobenzene sulfonic acid.

20, 10, and 5 mg/0.8 mL per rat in 50% ethanol, dose-dependently induced acute inflammation and damage in the colon tissue of rats (Figure 1). The results indicate that the higher the dose TNBS used, the more severe the inflammation and damage induced. As shown in macroscopic appearance and H and E sections (Figure 1A and B), high dose TNBS (20 mg/rat) induced multiple larger and deeper ulcerations, and dense inflammatory cell infiltration compared to that treated with low dose TNBS.

As shown in Figure 2, four weeks after TNBS (5-20 mg/rat) administration, there was no significant difference in MPO activity between TNBS-treated rats and the control groups, suggesting no acute inflammation was left at this period. However, results from pathological evaluation showed that the histological scores in high dose (20 mg/rat) and median dose (10 mg/rat) TNBS-treated groups were still significantly higher compared to that of the control (P < 0.05), but no significant difference was found between low dose TNBS-treated rats and the control, suggesting low dose TNBS-treated rats had completely recovered from the initial inflammation at 4 wk post TNBS. As shown in Figure 2A and B, the colons from high and medium dose TNBS treated rats lost their normal appearance, and more collagen was found in the submucosa and smooth muscle in Masson staining sections, suggesting the occurrence of fibroplasia.

Effect of trinitrobenzene sulfonic acid administration position, and ethanol percentage on the visceral hyperalgesia

To investigate whether the low dose TNBS (5 mg/0.8 mL per rat)-treated rats acquired long-lasting visceral hyperalgesia after inflammation resolution, AWR test was applied to all these TNBS-treated rats at 4 and 8 wk after TNBS administration. As shown in Figure 4, at 4 wk after TNBS administration, the pain threshold pressure in all TNBS-treated rats was decreased significantly compared to the control (P < 0.05), but no significant difference was found among these TNBS-treated rats. At 8 wk after TNBS administration, the pain threshold pressure in rats treated with TNBS at the depth of 8 cm was still significantly decreased compared to that of the controls (P < 0.05), but no significant difference was found in rats treated with TNBS at 4 cm from anus or in 25% ethanol.

Enterochromaffin cell hyperplasia in trinitrobenzene sulfonic acid-induced post-infectious irritable bowel syndrome rat model

To investigate whether the rats treated with low dose TNBS (5 mg/0.8 mL per rat, in 50% ethanol) at 8 cm from anus also acquired other features of PI-IBS, the EC cell number and 5-HT content in the proximal and distal colon tissues were further tested at 4 and 8 wk after TNBS administration. As shown in Figure 5, compared to the control, 5-HT content in the proximal colon, but not the distal colon, were significantly increased, with 32% (P < 0.01) and 23% (P < 0.05) increased at 4 and 8 wk after TNBS administration, respectively. A
similar trend can also be found in the EC cell number; i.e., there were 68% and 60% increases at 4 and 8 wk after TNBS administration, respectively ($P < 0.01$), suggesting this TNBS-induced PI-IBS model also presents EC cell hyperplasia in the colon tissue.

**DISCUSSION**

TNBS is an agent commonly used in inducing post-inflammatory IBS model currently. Concerning the variations in developing a protocol of the TNBS-induced PI-IBS rat model and the three necessary features of PI-IBS animal model (i.e., initial inflammation/infection, inflammation/infection resolution, and acquired symptoms of IBS), the present study investigated the effects of TNBS dosage and concentration, intracolonic TNBS administration position, and ethanol percentage on the development of the TNBS-induced PI-IBS rat model. Our results showed that: (1) TNBS induced dose- and concentration-dependent acute inflammation and inflammation resolution at the dose range of 5-20 mg/rat; (2) Intracolonic TNBS administration position affected the persistence of later acquired visceral hyperalgesia, but not the initial inflammation severity; (3) Ethanol percentage affected the TNBS-induced inflammation severity and later acquired visceral hyperalgesia, and low ethanol percentage reduced the degree of TNBS-induced acute inflammation and shortened the persistence of acquired visceral hyperalgesia; and (4) The protocol with TNBS at 5 mg/0.8 mL per rat, dissolved in 50% ethanol, intracolonically administered 8 cm from anus may be a proper protocol in which rats can recover completely from the
initial inflammation but acquire persistent visceral hyperalgesia and EC cell hyperplasia at 4 wk after TNBS administration. As shown in our results, in the dose range of 5-20

Figure 2  Effect of trinitrobenzene sulfonic acid dosage on severity of acute inflammation and inflammation resolution. The colon tissue was collected at 4 wk after trinitrobenzene sulfonic acid (TNBS) administration. Panel A depicts the appearance of colon tissue in saline (A1), high dose TNBS (20 mg/rat, A2), medium dose TNBS (10 mg/rat, A3), and low dose TNBS (5 mg/rat, A4)-treated rats; Panel B depicts the representative histological changes of colon tissue in saline (B1), high dose TNBS (B2), medium dose TNBS (B3), and low dose TNBS (B4)-treated rats (Masson trichrome staining, 100×); Statistical analysis of myeloperoxidase (MPO) activity is shown in panel (C), and pathological score in panel (D). Data are shown as mean ± SE, n = 4 per group. \(^{b}P < 0.01\) vs saline-treated group (one-way analysis of variance, Student-Newman-Keuls).
mg per rat, the higher the dose of TNBS, the more severe the acute inflammation and mucosa damage. This finding is consistent with previous reports that the severity and duration in TNBS-induced inflammation is dose-dependent\cite{13,14,17}. It is notable that the same dose of TNBS (20 mg/rat) when given to rats in different vehicle volumes induced different degrees of damage; a higher TNBS concentration (50 mg/mL) induced
more severe damage, even causing animal death in the acute phase. Our pathological results also showed that high-concentration TNBS-treated rats presented localized more severe inflammation and deeper ulcerations around the position of TNBS administration, which may be responsible for the occurrence of colitis complications, i.e., intestinal obstruction, intra-abdominal infection, and animal death. Concerning the fact that inflammation severity and duration have close correlation with TNBS dosage, the effects of TNBS dosage on inflammation resolution was assessed at 4 wk after TNBS administration. According to the pathologist’s suggestion, fibroplasia evaluation index was added into the pathological evaluation criteria for the first time, so as to exactly evaluate inflammation resolution. Our results showed that the animals receiving low dose TNBS (5 mg/rat) recovered completely at 4 wk after TNBS administration, but those receiving high (20 mg/rat) and medium (10 mg/rat) dose were not recovered. This result seems to somewhat conflict with the finding from a previous study in which the rats receiving TNBS (5-20 mg/rat, in 25% ethanol) all recovered after 4 wk [14]. We speculate that this discrepancy may come from the protocol differences between these two studies, such as ethanol percentage, animal strain, or evaluation criteria. Consistent with our findings, the previous study showed that colonic inflammation induced by TNBS (30 mg/rat, in 50% ethanol) lasted for at least 8 wk [17], suggesting the inflammation resolution is also dose-dependent. Based on previous findings and our results, TNBS dosage plays a critical role in TNBS-induced inflammation severity and resolution, and low dose TNBS (5 mg/rat)-induced inflammation can recover completely at 4 wk after TNBS administration.

Currently, 25% and 50% ethanol are both used as the carrier of TNBS in establishing TNBS-induced PI-IBS model and TNBS is commonly given to rats at the depth of either 4 cm or 8 cm from the anus. Based on low dose TNBS (5 mg/0.8 mL per rat) selection, we further investigated the effects of ethanol percentage and intracolonic administration position on the severity and resolution of TNBS-induced inflammation. Our results showed that rats treated with low dose TNBS at a depth of 4 cm or 8 cm presented similar inflammation severity and resolution, while the rats treated with TNBS in 25% ethanol developed milder non-ulcer inflammation compared to those treated with TNBS in 50% ethanol. As the carrier of TNBS, ethanol is known as a breaker to the mucosal barrier, and 30%-50% ethanol alone has been proved to induce acute inflammation and hyperemia [18,28]. Moreover, previous study have shown that 30% ethanol alone induced small areas of necrosis and hyperemia in the colon [18]. These findings indicate that ethanol alone can induce concentration-dependent inflammation, and can be considered

Figure 5 Persistent increases of enterochromaffin cell number and serotonin content in the colon tissue of trinitrobenzene sulfonic acid-induced post-infectious irritable bowel syndrome rat model. The colon tissue was collected at 4 wk and 8 wk after trinitrobenzene sulfonic acid (TNBS) administration. Panel A depicts the representative enterochromaffin (EC) cell staining in colon mucosa, the samples were from rats treated with saline (A1), or TNBS (A2) at 4 wk post TNBS (Scale bar, 100 μm). Statistical analysis of serotonin content is shown in panel (B), and EC cell number in panel (C). Data are shown as mean ± SE, n = 5 per group. *P < 0.05, **P < 0.01 vs saline-treated rats. 5-HT: 5-hydroxytryptamine.

Qin HY et al. TNBS-induced PI-IBS rat model
as an invasive helper in enhancing the effects of TNBS. Therefore, it seems reasonable that milder inflammation was induced in rats treated with equal dose of TNBS (5 mg/rat) but in lower ethanol percentage (25%). These results can also explain why high dose or high concentration TNBS have also been used by some researchers in establishing a PI-IBS model: low concentration ethanol may ameliorate the effects of TNBS.

Visceral hyperalgesia, the major feature of IBS, was further tested in low dose TNBS (5 mg/0.8 mL per rat) treated rats. From 4 wk to 8 wk post TNBS intracolonic administration at a depth of 8 cm, significant and persistent decrease in visceral pain threshold pressure was found, while the intracolic TNBS administration at a depth of 4 cm or in 25% ethanol presented short-term acquired visceral hyperalgesia. Nowadays, the duration and severity of inflammation are considered as important risk factors in the development of PI-IBS, and severe inflammation which results in deep impairment of the underlying nerve fibers has been proposed to play an important role in the pathogenesis of IBS. Based on the above evidence, we believe the unstable visceral hyperalgesia (i.e., lasting for less than 4 wk) in rats treated with TNBS in 25% ethanol may have close correlation with the mild non-ulceration observed at the acute phase of inflammation. These results also provide us with the information that mild inflammation, even without ulceration, can induce later short-term visceral hyperalgesia. However, it seems interesting that the same dose of TNBS when given at the different positions of colon (transverse vs descending) induced different features of acquired visceral hyperalgesia (persistent vs short-term), even though the TNBS-induced acute inflammation and damage was similar at first. Considering the unclear and complex pathogenesis of visceral hypersensitivity in PI-IBS, it is not easy to provide a clear explanation for the current findings. However, during the acute phase of TNBS-induced inflammation, obvious colon dilation and a large amount of retained feces were found in the inflamed transverse colon, but not in the inflamed distal colon. We speculate that the persistent colonic inflammation and dilation may play important roles in enteric nerve system plasticity, and thus influence the feature of acquired visceral hypersensitivity. Currently, peripheral and central neuroplastic changes are considered to be associated with post-inflammation persistent visceral hypersensitivity. It is also well known that transient colorectal distension in the neonatal period can result in chronic visceral hypersensitivity and motility dysfunction in adulthood, and the underlying mechanism is thought to be associated with alterations in peripheral and central nerve systems. Moreover, considering the different structure and functions of the transverse and descending colons, the regional differences in gut flora, mast cells, and EC cells may also contribute to the different feature of acquired visceral hypersensitivity observed in our study. Further studies are needed to clarify these issues.

EC cell hyperplasia has been found in the colonic specimens of IBS and PI-IBS patients, and EC cell hyperplasia has been reported to play important role in the development of visceral hypersensitivity in IBS patients. To identify whether visceral hyperalgesia is also accompanied with EC cell hyperplasia in the TNBS-induced PI-IBS rat model, EC cell number and 5-HT content were further investigated in the proximal and distal colon of PI-IBS rats. As shown in our study, the EC cell number and 5-HT content in the proximal colon, but not the distal colon, were significantly and persistently increased in this TNBS model, suggesting the occurrence of EC cell hyperplasia. However, this result differed from the finding from IBS patients, as EC cell hyperplasia in rectal mucosa was commonly reported. This may be explained by the different distribution of

---

**Table 5 Detailed protocols in developing trinitrobenzene sulfonic acid induced post-inflammatory irritable bowel syndrome model in Sprague-Dawley rats**

| Procedures | Cautions |
|------------|----------|
| 1. 7-wk-old male Sprague-Dawley rats, fast 24 h before TNBS administration | Fresh preparation |
| 2. Mix 1 volume of 12.5 mg/mL TNBS-saline solution with 1 volume of absolute ethanol | Ensure TNBS solution remains completely in the colon; |
| 3. Weight and anesthetized rats with chloral hydrate (350 mg/kg, i.p.) | Keep the rats warm |
| 4. Insert a catheter into the colon at 8 cm from anus | On day 3, body weight decreased by 10%-20% with unformed bloody stool; |
| 5. Keep the rat with head-down vertical position, instill 0.8 mL TNBS solution slowly into the colon lumen within 1 min | On day 7, body weight regained and reached the original level, the stool become formed but still soft; |
| 6. Keep the rat in head-down vertical position for 1 min before gently removing the catheter | From day 7 to day 28, body weight increased smoothly, and finally reached the control level |
| 7. Put the rats in a mound of bedding in head-down position until consciousness recovery |  |
| 8. On day 3, 7, 14, 21 and 28, observe and weight the rats |  |
EC cells in the gut mucosa between human beings and rats: the vast majority of EC cells in humans mainly reside in the small intestine and rectum while the major source of EC cells in rats largely locates in the cecum with a decline trend from the proximal to the distal colon. Consistent with our findings, previous studies also showed that 5-HT content in the rat proximal colon tissue was significantly higher (about 5 fold) than that in the distal colon. Therefore, it seems that EC cell hyperplasia in the proximal colon can be regarded as one of the features of the TNBS-induced PI-IBS rat model.

This present study, for the first time, showed that TNBS dosage and concentration, position of intracolonic TNBS administration, and ethanol percentage play important roles in developing the TNBS-induced PI-IBS model in Sprague-Dawley rats, suggesting more attention should be paid to these factors when developing a PI-IBS model with TNBS. Concerning the gene differences among animal strains, the protocol set up here may need some modulation when other rat strains except Sprague-Dawley rats, are used. Though this TNBS model presented persistent visceral hyperalgesia and EC cell hyperplasia for as long as 4 wk, more studies are still needed to observe the long-lasting visceral hyperalgesia and identify other features of PI-IBS in this model.

In the present study, we found out that the protocol with TNBS at 5 mg/0.8 mL per rat, dissolved in 50% ethanol, intracolically administered at 8 cm from the anus resulted in persistent visceral hyperalgesia and colonic EC cell hyperplasia after complete recovery from the initial inflammation in rats. With this protocol, low-dose TNBS-induced mild mucosa damage and colonic inflammation is reproducible without any animal loss; visceral hyperalgesia and EC cell hyperplasia which last for at least 4 wk occur as early as 4 wk after TNBS administration. The details of this protocol are presented in Table 5. Ensuring the results from different laboratories would be comparable, we believe that widespread adoption of a recommended protocol will save a great quantity of time and resources.

ACKNOWLEDGMENTS

We are very grateful to Dr. Zhi Li for his kind suggestion in setting up pathological criteria.

REFERENCES

1. Barbara G, Cremo C, Pallotti F, De Giorgio R, Stanghellini V, Corinaldesi R. Postinfectious irritable bowel syndrome. J Pediatr Gastroenterol Nutr 2009; 48 Suppl 2: S95-S97
2. Neal KR, Barker L, Spiller RC. Prognosis in post-infective irritable bowel syndrome: a six year follow up study. Gut 2002; 51: 410-413
3. Dunlop SP, Jenkins D, Neal KR, Spiller RC. Relative importance of enterochromaffin cell hyperplasia, anxiety, and depression in postinfectious IBS. Gastroenterology 2003; 125: 1651-1659
4. Gwee KA, Leong YL, Graham C, McKendrick MW, Collins SM, Walters SJ, Underwood JE, Read NW. The role of psychological and biological factors in postinfective gut dysfunction. Gut 1999; 44: 400-406
5. Chaudhary YA, Truelove SC. The irritable colon syndrome. A study of the clinical features, predisposing causes, and prognosis in 130 cases. Q J Med 1962; 31: 307-322
6. Thabane M, Marshall JK. Post-infectious irritable bowel syndrome. World J Gastroenterol 2009; 15: 3591-3596
7. Qin HY, Wu JC, Tong XD, Sung JJ, XuHX, Bian ZX. Systematic review of animal models of post-infectious/post-inflammatory irritable bowel syndrome. J Gastroenterol 2011; 46: 164-174
8. Collins SM, Piche T, Rampal P. The putative role of inflammation in the irritable bowel syndrome. Gut 2001; 49: 743-745
9. Lamb K, Zhong F, Gehbarts F, Biellefildt K. Experimental colitis in mice and sensitization of converging visceral and somatic afferent pathways. Am J Physiol Gastrointest Liver Physiol 2006; 290: G451-G457
10. Bergin AJ, Donnelly TC, McKendrick MW, Read NW. Changes in anorectal function in persistent bowel disturbance following salmonella gastroenteritis. Eur J Gastroenterol Hepatol 1993; 5: 617-620
11. Barbara G, Cremo C, Gargano L, Giorgio RD, Cogliandro R, Stanghellini V, Corinaldesi R. T394 Mesalazine Treatment for Intestinal Immune Activation in Patient with Irritable Bowel Syndrome: A Randomized Controlled Pilot Trial. Gastroenterology 2008; 134: A-546
12. Kim HS, Berstad A. Experimental colitis in animal models. Scand J Gastroenterol 1992; 27: 529-537
13. Menozzi A, Pozzoli C, Poli E, Lazzaretti M, Grandi D, Qin HY et al. TNBS-induced PI-IBS rat model
Coruzzi G. Long-term study of TNBS-induced colitis in rats: focus on mast cells. *Inflamm Res* 2006; 55: 416-422

14 **Adam B**, Liebrig T, Gschoßmann JM, Krippner C, Scholl F, Ruwe M, Holtmann G. Severity of mucosal inflammation as a predictor for alterations of visceral sensory function in a rat model. *Pain* 2006; 123: 179-186

15 **Winchester WJ**, Johnson A, Hicks GA, Gebhart GF, Greenwood-van Meerveld B, McLean PG. Inhibition of endothelial cell adhesion molecule expression improves colonic hyperaesthesia. *Neurogastroenterol Motil* 2009; 21: 189-196

16 **Collins SM**, McHugh K, Jacobson K, Khan I, Riddell R, Murase K, Weingarten HP. Previous inflammation alters the response of the rat colon to stress. *Gastroenterology* 1996; 111: 1599-1615

17 **Morris GP**, Beck PL, Herridge MS, Depew WT, Szewczuk MR, Wallace JL. Hapten-induced model of chronic inflammation and ulceration in the rat colon. *Gastroenterology* 1989; 96: 795-803

18 **Diop L**, Raymond F, Fargeau H, Petoux F, Chovet M, Doherty AM. Pregabalim (CI-1008) inhibits the trinitrobenzene sulfonic acid-induced colonic allosy in the rat. *J Pharmacol Exp Ther* 2002; 302: 1013-1022

19 **Asfaha S**, MacNaughton WK, Appleyard CB, Chadee K, Wallace JL. Persistent epithelial dysfunction and bacterial translocation after resolution of intestinal inflammation. *Am J Physiol Gastrointest Liver Physiol* 2001; 281: G635-G644

20 **Greenwood-Van Meerveld B**, Johnson AC, Foreman RD, Linderoth B. Spinal cord stimulation attenuates visceromotor reflexes in a rat model of post-inflammatory colonic hyper-sensitivity. *Auton Neurosci* 2005; 122: 69-76

21 **Ferrini MG**, Kovancez I, Sanchez S, Umech C, Rajfer J, Gonzalez-Cadavid NF. Fibrosis and loss of smooth muscle distribution in the corpora cavernosa precede corporeal veno-occlusive dysfunction (CVOD) induced by experimental cavernosal nerve damage in the rat. *J Sex Med* 2009; 6: 415-428

22 **Gue M**, Bonboncine C, Fioramonj I, More J, Del Rio-Lachèze C, Coméra C, Buño L. Stress-induced enhancement of colitis in rats: CRF and arginine vasopressin are not involved. *Am J Physiol* 1997; 272: G84-G91

23 **Fabi A**, Ar’Rajab A, Johansson ML, Willén R, Andersson R, Molin G, Bengmark S. The effect of exogenous administration of Lactobacillus reuteri R2LC and oat fiber on acetic acid-induced colitis in the rat. *Scand J Gastroenterol* 1993; 28: 155-162

24 **Krawisz JE**, Sharon P, Stenson WF. Quantitative assay for acute intestinal inflammation based on myeloperoxidase activity. Assessment of inflammation in rat and hamster models. *Gastroenterology* 1984; 87: 1344-1350

25 **Al-Chaer ED**, Kawasaki M, Pasricha PJ. A new model of chronic visceral hypersensitivity in adult rats induced by colon irritation during postnatal development. *Gastroenterology* 2000; 119: 1276-1285

26 **Grimaldi L**, Silver stains demonstrating neuroendocrine cells. *Biotech Histochew* 2004; 79: 37-44

27 **Qi SD**, Tian SL, Xu HX, Sung JJ, Bian ZX. Quantification of luminal released serotonin in rat proximal colon by capillary electrophoresis with laser-induced fluorescence detection. *Anal Bioanal Chem* 2009; 393: 2059-2066

28 **Asfaha S**, Bell CJ, Wallace JL, MacNaughton WK. Prolonged colonic epithelial hyporesponsiveness after colitis: role of inducible nitric oxide synthase. *Am J Physiol* 1999; 276: G703-G710

29 **Neal KR**, Hebden J, Spiller R. Prevalence of gastrointestinal symptoms six months after bacterial gastroenteritis and risk factors for development of the irritable bowel syndrome: postal survey of patients. *BMJ* 1997; 314: 779-782

30 **Wang LH**, Fang XC, Pan CZ. Bacillary dysentery as a causative factor of irritable bowel syndrome and its pathogenesis. *Gut* 2004; 53: 1096-1101

31 **Hughes PA**, Brierley SM, Blackshaw LA. Post-inflammatory modification of colonic afferent mechanosensitivity. *Clin Exp Pharmacol Physiol* 2009; 36: 1034-1040

32 **Chaloner A**, Rao A, Al-Chaer ED, Greenwood-Van Meerveld B. Importance of neural mechanisms in colonic mucosal and muscular dysfunction in adult rats following neonatal colonic irritation. *Int J Des Neurosci* 2010; 28: 99-103

33 **Lin C**, Al-Chaer ED. Long-term sensitization of primary afferents in adult rats exposed to neonatal colon pain. *Brain Res* 2003; 971: 73-82

34 **Meslin JC**, Fontaine N, Andrieux C. Variation of mucin distribution in the rat intestine, caecum and colon: effect of the bacterial flora. *Comp Biochem Physiol A Mol Integr Physiol* 1999; 123: 235-239

35 **Furgal A**, Litwin JA. Distribution of mast cells along and across successive segments of the rat digestive tract: a quantitative study. *Folia Histochew Cytohew* 1998; 36: 19-27

36 **Portela-Gomes GM**, Grimelius L, Petersson R, Bergström R. Enterochromaffin GM cells in the rat gastrointestinal tract. Aspects of factors influencing quantification. *Ups J Med Sci* 1984; 89: 189-203

37 **Lee KJ**, Kim YB, Kim JH, Kwon HC, Kim DK, Cho SW. The alteration of enterochromaffin cell, mast cell, and lamina propria T lymphocyte numbers in irritable bowel syndrome and its relationship with psychological factors. *J Gastroentorol Hepatol* 2008; 23: 1689-1694

38 **Dunlop SP**, Jenkins D, Neal KR, Spiller RC. Relative importance of enterochromaffin cell hyperplasia, anxiety, and depression in post-infectious IBS. *Gastroenterology* 2003; 125: 1651-1659

39 **Spiller RC**, Jenkins D, Thornley JP, Hebden JM, Wright T, Skinner M, Neal KR. Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome. *Gut* 2000; 47: 804-811

40 **Mawe GM**, Coates MD, Moses PL. Review article: intestinal serotonin signalling in irritable bowel syndrome. *Aliment Pharmacol Ther* 2006; 23: 1067-1076

41 **Park JH**, Rhee PL, Kim G, Lee JH, Kim YH, Kim JJ, Rhee JC, Song SY. Enteroendocrine cell counts correlate with visceral hypersensitivity in patients with diarrhoea-predominant irritable bowel syndrome. *Neurogastroenterol Motil* 2006; 18: 539-546

42 **Sjöland K**, Sandén G, Häkanson R, Sundler F. Endocrine cells in human intestine: an immunocytochemical study. *Gastroenterology* 1983; 85: 1120-1136

43 **Tsukamoto K**, Ariga H, Mantuy C, Pappas TN, Yanagi H, Yamamura T, Takahashi T. Luminally released serotonin stimulates colonic motility and accelerates colonic transit in rats. *Am J Physiol Regul Integr Comp Physiol* 2007; 293: R64-R69

44 **Bian ZX**, Qin HY, Tian SL, Qi SD. Combined effect of early life stress and acute stress on colonic sensory and motor responses through serotonin pathways: differences between proximal and distal colon in rats. *Stress* 2011; 14: 448-458

S-Editor Gou SX  L-Editor O’Neill M  E-Editor Li JY